{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:26:14Z","timestamp":1791584774265,"version":"4.3.4"},"reference-count":186,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["02\/(0354)\/19\/EMRII"],"award-info":[{"award-number":["02\/(0354)\/19\/EMRII"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Alzheimer\u2019s disease (AD) is a complex neurological disorder and multiple pathological factors are believed to be involved in the genesis and progression of the dis-ease. A number of hypothesis including Acetylcholinesterase, Monoamine oxidase, \u03b2-Amyloid, Tau protein etc. have been proposed for the initiation and progression of the disease. At present, acetylcholine esterase inhibitors and memantine (NMDAR antago-nist) are the only approved therapy for the symptomatic management of AD. Most of these single-target drugs have miserably failed in the treatment or halting the progression of the disease. Multi-factorial diseases like AD require complex treatment strategies that involve simultaneous modulation of a network of interacting targets. Since last few years, Multi-Target-Directed Ligands (MTDLs) strategy, drugs that can simultaneously hit mul-tiple targets, is being explored as an effective therapeutic approach for the treatment of AD. In the current review article, the authors have briefly described various pathogenic pathways associated with the AD. Importance of Multi-Target-Directed Ligands and their design strategies in recently reported articles have been discussed in detail. Potent leads identified through various structure-activity relationship studies and their drug like char-acteristics are described. Recently developed promising compounds have been summa-rized in the article. Some of these MTDLs with balanced activity profile against different targets have the potential to be developed as drug candidates for the treatment of AD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867328666210512005508","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T21:21:34Z","timestamp":1620854494000},"page":"1757-1803","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"29","author":[{"given":"Rakesh","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Chemistry, School of Basic and Applied\nSciences, Central University of Punjab, Bathinda, Punjab, 151001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda,\nPunjab, 151001, India"},{"name":"Laboratory of Organic and Medicinal\nChemistry, Department of Chemistry, Central University of Punjab, Bathinda, Punjab, 151001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda,\nPunjab, 151001, India"},{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan,\nG.T Road, Moga, Punjab, 142001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Thakur","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda,\nPunjab, 151001, India"},{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University,\n250 Wuxing Street, Taipei 11031, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Ranjan","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda,\nPunjab, 151001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.1132814","volume":"314","author":"Goedert M.","year":"2006","unstructured":"Goedert M.; Spillantini M.G.; A century of Alzheimer\u2019s disease. Science 2006,314(5800),777-781","journal-title":"Science"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jalz.2017.02.001","volume":"13","author":"Association A.","year":"2017","unstructured":"Association A.; 2017 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2017,13(4),325-373","journal-title":"Alzheimers Dement"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","author":"Association A.","year":"2018","unstructured":"Association A.; 2018 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2018,14(3),367-429","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210958","volume":"14","author":"Cimler R.","year":"2019","unstructured":"Cimler R.; Maresova P.; Kuhnova J.; Kuca K.; Predictions of Alzheimer\u2019s disease treatment and care costs in European countries. PLoS One 2019,14(1)","journal-title":"PLoS One"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.neurobiolaging.2008.09.016","volume":"31","author":"Dorfman V.B.","year":"2010","unstructured":"Dorfman V.B.; Pasquini L.; Riudavets M.; L\u00f3pez-Costa J.J.; Villegas A.; Troncoso J.C.; Lopera F.; Casta\u00f1o E.M.; Morelli L.; Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer\u2019s disease. Neurobiol Aging 2010,31(10),1743-1757","journal-title":"Neurobiol Aging"},{"key":"ref=6","first-page":"1134","volume":"25","author":"Alzheimer A.","year":"1906","unstructured":"Alzheimer A.; \u00dcber einen eigenartigen schweren Erkrankungsproze\u03b2 der Hirnrincle. Neurol Central 1906,25,1134","journal-title":"Neurol Central"},{"key":"ref=7","first-page":"15059","author":"Masters C.L.","year":"2015","unstructured":"Masters C.L.; Bateman R.; blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers 2015,15059","journal-title":"Nat Rev Dis Primers"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"Association A.","year":"2013","unstructured":"Association A.; 2013 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2013,9(2),208-245","journal-title":"Alzheimers Dement"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.nic.2005.09.009","volume":"15","author":"Imbimbo B.P.","year":"2005","unstructured":"Imbimbo B.P.; Lombard J.; Pomara N.; Pathophysiology of Alzheimer\u2019s disease. Neuroimaging Clin N Am , ix.2005,15(4),727-753","journal-title":"Neuroimaging Clin N Am"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1192\/bjp.152.6.737","volume":"152","author":"Perry E.","year":"1988","unstructured":"Perry E.; Acetylcholine and Alzheimer\u2019s disease. Br J Psychiatry 1988,152(6),737-740","journal-title":"Br J Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/nbdi.1997.0147","volume":"4","author":"Wisniewski T.","year":"1997","unstructured":"Wisniewski T.; Ghiso J.; Frangione B.; Biology of A \u03b2 amyloid in Alzheimer\u2019s disease. Neurobiol Dis 1997,4(5),313-328","journal-title":"Neurobiol Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1021\/ml300058m","volume":"3","author":"Kung H.F.","year":"2012","unstructured":"Kung H.F.; The \u03b2-amyloid hypothesis in Alzheimer\u2019s disease: Seeing is believing. ACS Med Chem Lett 2012,3(4),265-267","journal-title":"ACS Med Chem Lett"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","volume":"110","author":"Kennedy B.P.","year":"2003","unstructured":"Kennedy B.P.; Ziegler M.G.; Alford M.; Hansen L.A.; Thal L.J.; Masliah E.; Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease. J Neural Transm (Vienna) 2003,110(7),789-801","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biom6010006","volume":"6","author":"\u0160imi\u0107 G.","year":"2016","unstructured":"\u0160imi\u0107 G.; Babi\u0107 Leko M.; Wray S.; Harrington C.; Delalle I.; Jovanov-Milo\u0161evi\u0107 N.; Ba\u017eadona D.; Bu\u00e9e L.; de Silva R.; Di Giovanni G.; Wischik C.; Hof P.R.; Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 2016,6(1),6","journal-title":"Biomolecules"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0925-4439(00)00040-5","volume":"1502","author":"Smith M.A.","year":"2000","unstructured":"Smith M.A.; Rottkamp C.A.; Nunomura A.; Raina A.K.; Perry G.; Oxidative stress in Alzheimer\u2019s disease. Biochim Biophys Acta 2000,1502(1),139-144","journal-title":"Biochim Biophys Acta"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","volume":"43","author":"Garcia-Alloza M.","year":"2005","unstructured":"Garcia-Alloza M.; Gil-Bea F.J.; Diez-Ariza M.; Chen C.P.; Francis P.T.; Lasheras B.; Ramirez M.J.; Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease. Neuropsychologia 2005,43(3),442-449","journal-title":"Neuropsychologia"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00002093-199509020-00005","volume":"9","author":"Cummings J.L.","year":"1995","unstructured":"Cummings J.L.; Ross W.; Absher J.; Gornbein J.; Hadjiaghai L.; Depressive symptoms in Alzheimer disease: Assessment and determinants. Alzheimer Dis Assoc Disord 1995,9(2),87-93","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1021\/ol006046e","volume":"2","author":"M\u00fcller T.J.","year":"2000","unstructured":"M\u00fcller T.J.; Braun R.; Ansorge M.; A novel three-component one-pot pyrimidine synthesis based upon a coupling-isomerization sequence. Org Lett 2000,2(13),1967-1970","journal-title":"Org Lett"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"42660","DOI":"10.1039\/C6RA00302H","volume":"6","author":"Kumar B.","year":"2016","unstructured":"Kumar B.; Mantha A.K.; Kumar V.; Recent developments on the structure\u2013activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Advances 2016,6(48),42660-42683","journal-title":"RSC Advances"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","volume":"336","author":"Sano M.","year":"1997","unstructured":"Sano M.; Ernesto C.; Thomas R.G.; Klauber M.R.; Schafer K.; Grundman M.; Woodbury P.; Growdon J.; Cotman C.W.; Pfeiffer E.; Schneider L.S.; Thal L.J.; A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study. N Engl J Med 1997,336(17),1216-1222","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/0929867003375191","volume":"7","author":"Sugimoto H.","year":"2000","unstructured":"Sugimoto H.; Yamanishi Y.; Iimura Y.; Kawakami Y.; Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 2000,7(3),303-339","journal-title":"Curr Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1021\/cr040415t","volume":"106","author":"Marco-Contelles J.","year":"2006","unstructured":"Marco-Contelles J.; do Carmo Carreiras M.; Rodr\u00edguez C.; Villarroya M.; Garc\u00eda A.G.; Synthesis and pharmacology of galantamine. Chem Rev 2006,106(1),116-133","journal-title":"Chem Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","volume":"36","author":"Anand P.","year":"2013","unstructured":"Anand P.; Singh B.; A review on cholinesterase inhibitors for Alzheimer\u2019s disease. Arch Pharm Res 2013,36(4),375-399","journal-title":"Arch Pharm Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nm0908-894","volume":"14","author":"Gura T.","year":"2008","unstructured":"Gura T.; Hope in Alzheimer\u2019s fight emerges from unexpected places. Nat Med 2008,14(9),894","journal-title":"Nat Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.phrs.2003.12.027","volume":"50","author":"Racchi M.","year":"2004","unstructured":"Racchi M.; Mazzucchelli M.; Porrello E.; Lanni C.; Govoni S.; Acetylcholinesterase inhibitors: Novel activities of old molecules. Pharmacol Res 2004,50(4),441-451","journal-title":"Pharmacol Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2174\/092986708785909067","volume":"15","author":"Mu\u00f1oz-Torrero D.","year":"2008","unstructured":"Mu\u00f1oz-Torrero D.; Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer\u2019s disease. Curr Med Chem 2008,15(24),2433-2455","journal-title":"Curr Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3233\/JAD-143084","volume":"45","author":"Matsuzono K.","year":"2015","unstructured":"Matsuzono K.; Hishikawa N.; Ohta Y.; Yamashita T.; Deguchi K.; Nakano Y.; Abe K.; Combination therapy of cholinesterase inhibitor (donepezil or galantamine) plus memantine in the Okayama Memantine Study. J Alzheimers Dis 2015,45(3),771-780","journal-title":"J Alzheimers Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jagp.2015.08.006","volume":"23","author":"Small G.W.","year":"2015","unstructured":"Small G.W.; Greenfield S.; Current and future treatments for Alzheimer disease. Am J Geriatr Psychiatry 2015,23(11),1101-1105","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"Yiannopoulou K.G.","year":"2013","unstructured":"Yiannopoulou K.G.; Papageorgiou S.G.; Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disorder 2013,6(1),19-33","journal-title":"Ther Adv Neurol Disorder"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.2174\/1568026616666160927160620","volume":"17","author":"de Oliveira Pedrosa M.","year":"2017","unstructured":"de Oliveira Pedrosa M.; Duarte da Cruz R.M.; de Oliveira Viana J.; de Moura R.O.; Ishiki H.M.; Barbosa Filho J.M.; Diniz M.F.; Scotti M.T.; Scotti L.; Bezerra Mendonca F.J.; Hybrid compounds as direct multitarget ligands: A review. Curr Top Med Chem 2017,17(9),1044-1079","journal-title":"Curr Top Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1021\/acschemneuro.8b00069","volume":"9","author":"Oset-Gasque M.J.","year":"2018","unstructured":"Oset-Gasque M.J.; Marco-Contelles J.; Alzheimer\u2019s disease, the \u201cone-molecule, one-target\u201d paradigm, and the multitarget directed ligand approach. ACS Chem Neurosci 2018,9(3),401-403","journal-title":"ACS Chem Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0047-6374(01)00309-8","volume":"122","author":"Talesa V.N.","year":"2001","unstructured":"Talesa V.N.; Acetylcholinesterase in Alzheimer\u2019s disease. Mech Ageing Dev 2001,122(16),1961-1969","journal-title":"Mech Ageing Dev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"Bartus R.T.","year":"1982","unstructured":"Bartus R.T.; Dean R.L.; Beer B.; Lippa A.S.; The cholinergic hypothesis of geriatric memory dysfunction. Science 1982,217(4558),408-414","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archpsyc.1987.01800170041007","volume":"44","author":"Tariot P.N.","year":"1987","unstructured":"Tariot P.N.; Cohen R.M.; Sunderland T.; Newhouse P.A.; Yount D.; Mellow A.M.; Weingartner H.; Mueller E.A.; Murphy D.L.; L-deprenyl in Alzheimer\u2019s disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987,44(5),427-433","journal-title":"Arch Gen Psychiatry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1471-4159.2006.04258.x","volume":"100","author":"Avramovich-Tirosh Y.","year":"2007","unstructured":"Avramovich-Tirosh Y.; Amit T.; Bar-Am O.; Zheng H.; Fridkin M.; Youdim M.B.; Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer\u2019s disease. J Neurochem 2007,100(2),490-502","journal-title":"J Neurochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0166-2236(96)01030-2","volume":"20","author":"Hardy J.","year":"1997","unstructured":"Hardy J.; Amyloid, the presenilins and Alzheimer\u2019s disease. Trends Neurosci 1997,20(4),154-159","journal-title":"Trends Neurosci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","volume":"9","author":"Hardy J.","year":"2006","unstructured":"Hardy J.; Alzheimer\u2019s disease: The amyloid cascade hypothesis: An update and reappraisal. J Alzheimers Dis 2006,9(3)(Suppl.),151-153","journal-title":"J Alzheimers Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"Lin M.T.","year":"2006","unstructured":"Lin M.T.; Beal M.F.; Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006,443(7113),787-795","journal-title":"Nature"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"Goedert M.","year":"1989","unstructured":"Goedert M.; Spillantini M.G.; Jakes R.; Rutherford D.; Crowther R.A.; Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron 1989,3(4),519-526","journal-title":"Neuron"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2011.10.006","volume":"133","author":"Zheng W.","year":"2012","unstructured":"Zheng W.; Monnot A.D.; Regulation of brain iron and copper homeostasis by brain barrier systems: Implication in neurodegenerative diseases. Pharmacol Ther 2012,133(2),177-188","journal-title":"Pharmacol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnagi.2015.00042","volume":"7","author":"Villeneuve S.","year":"2015","unstructured":"Villeneuve S.; Wirth M.; La Joie R.; Are AD-typical regions the convergence point of multiple pathologies? Front Aging Neurosci 2015,7,42","journal-title":"Front Aging Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jamaneurol.2013.4013","volume":"70","author":"Wirth M.","year":"2013","unstructured":"Wirth M.; Villeneuve S.; Haase C.M.; Madison C.M.; Oh H.; Landau S.M.; Rabinovici G.D.; Jagust W.J.; Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013,70(12),1512-1519","journal-title":"JAMA Neurol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/WNL.0000000000000550","volume":"83","author":"Villeneuve S.","year":"2014","unstructured":"Villeneuve S.; Reed B.R.; Madison C.M.; Wirth M.; Marchant N.L.; Kriger S.; Mack W.J.; Sanossian N.; DeCarli C.; Chui H.C.; Weiner M.W.; Jagust W.J.; Vascular risk and A\u03b2 interact to reduce cortical thickness in AD vulnerable brain regions. Neurology 2014,83(1),40-47","journal-title":"Neurology"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1567205053585846","volume":"2","author":"Lipton S.A.","year":"2005","unstructured":"Lipton S.A.; The molecular basis of memantine action in Alzheimer\u2019s disease and other neurologic disorders: Low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005,2(2),155-165","journal-title":"Curr Alzheimer Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"Hooper C.","year":"2008","unstructured":"Hooper C.; Killick R.; Lovestone S.; The GSK3 hypothesis of Alzheimer\u2019s disease. J Neurochem 2008,104(6),1433-1439","journal-title":"J Neurochem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","volume":"182","author":"P\u00e9rez-Torres S.","year":"2003","unstructured":"P\u00e9rez-Torres S.; Cort\u00e9s R.; Tolnay M.; Probst A.; Palacios J.M.; Mengod G.; Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer\u2019s disease brains examined by in situ hybridization. Exp Neurol 2003,182(2),322-334","journal-title":"Exp Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/iub.1104","volume":"64","author":"Bollen E.","year":"2012","unstructured":"Bollen E.; Prickaerts J.; Phosphodiesterases in neurodegenerative disorders. IUBMB Life 2012,64(12),965-970","journal-title":"IUBMB Life"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-131535","volume":"39","author":"Morawski M.","year":"2014","unstructured":"Morawski M.; Schilling S.; Kreuzberger M.; Waniek A.; J\u00e4ger C.; Koch B.; Cynis H.; Kehlen A.; Arendt T.; Hartlage-R\u00fcbsamen M.; Demuth H.U.; Ro\u00dfner S.; Glutaminyl cyclase in human cortex: Correlation with (pGlu)-amyloid-\u03b2 load and cognitive decline in Alzheimer\u2019s disease. J Alzheimers Dis 2014,39(2),385-400","journal-title":"J Alzheimers Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","volume":"14","author":"Saido T.C.","year":"1995","unstructured":"Saido T.C.; Iwatsubo T.; Mann D.M.; Shimada H.; Ihara Y.; Kawashima S.; Dominant and differential deposition of distinct \u03b2-amyloid peptide species, A \u03b2 N3(pE), in senile plaques. Neuron 1995,14(2),457-466","journal-title":"Neuron"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.2174\/0929867327666200716113136","volume":"28","author":"Mal S.","year":"2021","unstructured":"Mal S.; Dwivedi A.R.; Kumar V.; Kumar N.; Kumar B.; Kumar V.; Role of Peroxisome Proliferated Activated Receptor gamma (PPAR\u03b3) in Different Disease States: Recent Updates. Curr Med Chem 2021,28(16),3193-3215","journal-title":"Curr Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1006\/bbrc.1998.9981","volume":"254","author":"Kitamura Y.","year":"1999","unstructured":"Kitamura Y.; Shimohama S.; Koike H.; Kakimura J-i.; Matsuoka Y.; Nomura Y.; Gebicke-Haerter P.J.; Taniguchi T.; Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-\u03b3 in Alzheimer\u2019s disease brains. Biochem Biophys Res Commun 1999,254(3),582-586","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"9796","DOI":"10.1523\/JNEUROSCI.23-30-09796.2003","volume":"23","author":"Sastre M.","year":"2003","unstructured":"Sastre M.; Dewachter I.; Landreth G.E.; Willson T.M.; Klockgether T.; van Leuven F.; Heneka M.T.; Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-\u03b3 agonists modulate immunostimulated processing of amyloid precursor protein through regulation of \u03b2-secretase. J Neurosci 2003,23(30),9796-9804","journal-title":"J Neurosci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"V66","DOI":"10.1055\/s-2005-919211","volume":"32","author":"Sastre M.","year":"2005","unstructured":"Sastre M.; Ro\u00dfner S.; Bogdanovic N.; Rosen E.; Dewachter I.; Borghgraef P.; Evert B.; Dumitrescu-Ozimek L.; Thal D.; Landreth G.;  NSAIDs repress BACE1 gene promoter activity by activation of PPARgamma Aktuelle Neurologie 2005,32(S 4),V66","journal-title":"NSAIDs repress BACE1 gene promoter activity by activation of PPARgamma Aktuelle Neurologie"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"10908","DOI":"10.1523\/JNEUROSCI.3987-04.2004","volume":"24","author":"Camacho I.E.","year":"2004","unstructured":"Camacho I.E.; Serneels L.; Spittaels K.; Merchiers P.; Dominguez D.; De Strooper B.; Peroxisome-proliferator-activated receptor \u03b3 induces a clearance mechanism for the amyloid-\u03b2 peptide. J Neurosci 2004,24(48),10908-10917","journal-title":"J Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1042\/BJ20050560","volume":"391","author":"d\u2019Abramo C.","year":"2005","unstructured":"d\u2019Abramo C.; Massone S.; Zingg J-M.; Pizzuti A.; Marambaud P.; Dalla Piccola B.; Azzi A.; Marinari U.M.; Pronzato M.A.; Ricciarelli R.; Role of peroxisome proliferator-activated receptor \u03b3 in amyloid precursor protein processing and amyloid \u03b2-mediated cell death. Biochem J 2005,391(Pt 3),693-698","journal-title":"Biochem J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/nn.2213","volume":"11","author":"Sanchez-Mejia R.O.","year":"2008","unstructured":"Sanchez-Mejia R.O.; Newman J.W.; Toh S.; Yu G-Q.; Zhou Y.; Halabisky B.; Ciss\u00e9 M.; Scearce-Levie K.; Cheng I.H.; Gan L.; Palop J.J.; Bonventre J.V.; Mucke L.; Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer\u2019s disease. Nat Neurosci 2008,11(11),1311-1318","journal-title":"Nat Neurosci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/nm.1868","volume":"14","author":"Du H.","year":"2008","unstructured":"Du H.; Guo L.; Fang F.; Chen D.; Sosunov A.A.; McKhann G.M.; Yan Y.; Wang C.; Zhang H.; Molkentin J.D.; Gunn-Moore F.J.; Vonsattel J.P.; Arancio O.; Chen J.X.; Yan S.D.; Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer\u2019s disease. Nat Med 2008,14(10),1097-1105","journal-title":"Nat Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.neurobiolaging.2007.12.022","volume":"30","author":"Bernardo A.","year":"2009","unstructured":"Bernardo A.; Harrison F.E.; McCord M.; Zhao J.; Bruchey A.; Davies S.S.; Jackson Roberts L.; Mathews P.M.; Matsuoka Y.; Ariga T.; Yu R.K.; Thompson R.; McDonald M.P.; Elimination of GD3 synthase improves memory and reduces amyloid-\u03b2 plaque load in transgenic mice. Neurobiol Aging 2009,30(11),1777-1791","journal-title":"Neurobiol Aging"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.1523\/JNEUROSCI.23-26-08867.2003","volume":"23","author":"Melchor J.P.","year":"2003","unstructured":"Melchor J.P.; Pawlak R.; Strickland S.; The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-\u03b2 (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003,23(26),8867-8871","journal-title":"J Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1523\/JNEUROSCI.1381-04.2004","volume":"24","author":"Caricasole A.","year":"2004","unstructured":"Caricasole A.; Copani A.; Caraci F.; Aronica E.; Rozemuller A.J.; Caruso A.; Storto M.; Gaviraghi G.; Terstappen G.C.; Nicoletti F.; Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer\u2019s brain. J Neurosci 2004,24(26),6021-6027","journal-title":"J Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1073\/pnas.90.7.2628","volume":"90","author":"Saito K.","year":"1993","unstructured":"Saito K.; Elce J.S.; Hamos J.E.; Nixon R.A.; Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 1993,90(7),2628-2632","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/npp.2009.197","volume":"35","author":"Kilgore M.","year":"2010","unstructured":"Kilgore M.; Miller C.A.; Fass D.M.; Hennig K.M.; Haggarty S.J.; Sweatt J.D.; Rumbaugh G.; Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology 2010,35(4),870-880","journal-title":"Neuropsychopharmacology"},{"key":"ref=64","first-page":"616","volume":"166","author":"Gauthier S.","year":"2002","unstructured":"Gauthier S.; Advances in the pharmacotherapy of Alzheimer\u2019s disease. CMAJ 2002,166(5),616-623","journal-title":"CMAJ"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuint.2008.06.005","volume":"53","author":"P\u00e1k\u00e1ski M.","year":"2008","unstructured":"P\u00e1k\u00e1ski M.; K\u00e1lm\u00e1n J.; Interactions between the amyloid and cholinergic mechanisms in Alzheimer\u2019s disease. Neurochem Int 2008,53(5),103-111","journal-title":"Neurochem Int"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0161-813X(03)00106-2","volume":"25","author":"Riederer P.","year":"2004","unstructured":"Riederer P.; Danielczyk W.; Gr\u00fcnblatt E.; Monoamine oxidase-B inhibition in Alzheimer\u2019s disease. Neurotoxicology 2004,25(1-2),271-277","journal-title":"Neurotoxicology"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"Selkoe D.J.","year":"2001","unstructured":"Selkoe D.J.; Alzheimer\u2019s disease: Genes, proteins, and therapy. Physiol Rev 2001,81(2),741-766","journal-title":"Physiol Rev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1021\/acschemneuro.7b00416","volume":"9","author":"Vitale R.M.","year":"2018","unstructured":"Vitale R.M.; Rispoli V.; Desiderio D.; Sgammato R.; Thellung S.; Canale C.; Vassalli M.; Carbone M.; Ciavatta M.L.; Mollo E.; Felicit\u00e0 V.; Arcone R.; Gavagnin Capoggiani M.; Masullo M.; Florio T.; Amodeo P.; In Silico identification and experimental validation of novel anti-alzheimer\u2019s multitargeted ligands from a marine source featuring a \u201c2-aminoimidazole plus aromatic group\u201d scaffold. ACS Chem Neurosci 2018,9(6),1290-1303","journal-title":"ACS Chem Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ana.410340312","volume":"34","author":"Wright C.I.","year":"1993","unstructured":"Wright C.I.; Geula C.; Mesulam M.M.; Neurological cholinesterases in the normal brain and in Alzheimer\u2019s disease: Relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993,34(3),373-384","journal-title":"Ann Neurol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/WNL.39.1.40","volume":"39","author":"Polinsky R.J.","year":"1989","unstructured":"Polinsky R.J.; Holmes K.V.; Brown R.T.; Weise V.; CSF acetylcholinesterase levels are reduced in multiple system atrophy with autonomic failure. Neurology 1989,39(1),40-44","journal-title":"Neurology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nsb732","volume":"9","author":"Binda C.","year":"2002","unstructured":"Binda C.; Newton-Vinson P.; Hub\u00e1lek F.; Edmondson D.E.; Mattevi A.; Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002,9(1),22-26","journal-title":"Nat Struct Biol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"Youdim M.B.","year":"2006","unstructured":"Youdim M.B.; Edmondson D.; Tipton K.F.; The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006,7(4),295-309","journal-title":"Nat Rev Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1086\/302562","volume":"65","author":"Shih J.C.","year":"1999","unstructured":"Shih J.C.; Thompson R.F.; Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 1999,65(3),593-598","journal-title":"Am J Hum Genet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1389450117666151209123402","volume":"18","author":"Kumar B.","year":"2017","unstructured":"Kumar B.; Gupta V.P.; Kumar V.; A perspective on monoamine oxidase enzyme as drug target: Challenges and opportunities. Curr Drug Targets 2017,18(1),87-97","journal-title":"Curr Drug Targets"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"621S","DOI":"10.1093\/ajcn\/71.2.621s","volume":"71","author":"Christen Y.","year":"2000","unstructured":"Christen Y.; Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000,71(2),621S-629S","journal-title":"Am J Clin Nutr"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.addr.2008.06.002","volume":"60","author":"Bortolato M.","year":"2008","unstructured":"Bortolato M.; Chen K.; Shih J.C.; Monoamine oxidase inactivation: From pathophysiology to therapeutics. Adv Drug Deliv Rev 2008,60(13-14),1527-1533","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"Hardy J.","year":"1991","unstructured":"Hardy J.; Allsop D.; Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 1991,12(10),383-388","journal-title":"Trends Pharmacol Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","volume":"101","author":"Walsh D.M.","year":"2007","unstructured":"Walsh D.M.; Selkoe D.J.; A beta oligomers - a decade of discovery. J Neurochem 2007,101(5),1172-1184","journal-title":"J Neurochem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3233\/JAD-170585","volume":"62","author":"Swerdlow R.H.","year":"2018","unstructured":"Swerdlow R.H.; Mitochondria and mitochondrial cascades in Alzheimer\u2019s disease. J Alzheimers Dis 2018,62(3),1403-1416","journal-title":"J Alzheimers Dis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-018-0354-2","volume":"10","author":"Sang S.","year":"2018","unstructured":"Sang S.; Pan X.; Chen Z.; Zeng F.; Pan S.; Liu H.; Jin L.; Fei G.; Wang C.; Ren S.; Jiao F.; Bao W.; Zhou W.; Guan Y.; Zhang Y.; Shi H.; Wang Y.; Yu X.; Wang Y.; Zhong C.; Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer\u2019s disease, whereas amyloid deposition does not. Alzheimers Res Ther 2018,10(1),26","journal-title":"Alzheimers Res Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","volume":"15","author":"Wang W.","year":"2020","unstructured":"Wang W.; Zhao F.; Ma X.; Perry G.; Zhu X.; Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: Recent advances. Mol Neurodegener 2020,15(1),30","journal-title":"Mol Neurodegener"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ejmech.2016.03.084","volume":"121","author":"Hroudov\u00e1 J.","year":"2016","unstructured":"Hroudov\u00e1 J.; Singh N.; Fi\u0161ar Z.; Ghosh K.K.; Progress in drug development for Alzheimer\u2019s disease: An overview in relation to mitochondrial energy metabolism. Eur J Med Chem 2016,121,774-784","journal-title":"Eur J Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1517\/14656566.4.12.2305","volume":"4","author":"Ferris S.H.","year":"2003","unstructured":"Ferris S.H.; Evaluation of memantine for the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother 2003,4(12),2305-2313","journal-title":"Expert Opin Pharmacother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/1381612825666191011102444","volume":"25","author":"Kabir M.T.","year":"2019","unstructured":"Kabir M.T.; Sufian M.A.; Uddin M.S.; Begum M.M.; Akhter S.; Islam A.; Mathew B.; Islam M.S.; Amran M.S.; Md Ashraf G.; NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for alzheimer\u2019s therapy. Curr Pharm Des 2019,25(33),3506-3518","journal-title":"Curr Pharm Des"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1039\/b401985g","volume":"13","author":"Brown D.R.","year":"2004","unstructured":"Brown D.R.; Kozlowski H.; Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases. Dalton Trans 2004,13(13),1907-1917","journal-title":"Dalton Trans"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnins.2016.00177","volume":"10","author":"Hughes R.E.","year":"2016","unstructured":"Hughes R.E.; Nikolic K.; Ramsay R.R.; One for all? Hitting multiple Alzheimer\u2019s disease targets with one drug. Front Neurosci 2016,10,177","journal-title":"Front Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"Cavalli A.","year":"2008","unstructured":"Cavalli A.; Bolognesi M.L.; Minarini A.; Rosini M.; Tumiatti V.; Recanatini M.; Melchiorre C.; Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008,51(3),347-372","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ejmech.2018.05.004","volume":"152","author":"Jalili-Baleh L.","year":"2018","unstructured":"Jalili-Baleh L.; Babaei E.; Abdpour S.; Nasir Abbas Bukhari S.; Foroumadi A.; Ramazani A.; Sharifzadeh M.; Abdollahi M.; Khoobi M.; A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer\u2019s disease. Eur J Med Chem 2018,152,570-589","journal-title":"Eur J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.neuropharm.2011.10.007","volume":"62","author":"Minarini A.","year":"2012","unstructured":"Minarini A.; Milelli A.; Tumiatti V.; Rosini M.; Simoni E.; Bolognesi M.L.; Andrisano V.; Bartolini M.; Motori E.; Angeloni C.; Hrelia S.; Cystamine-tacrine dimer: A new multi-target-directed ligand as potential therapeutic agent for Alzheimer\u2019s disease treatment. Neuropharmacology 2012,62(2),997-1003","journal-title":"Neuropharmacology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.bmc.2018.02.014","volume":"26","author":"Lu X.","year":"2018","unstructured":"Lu X.; He S.Y.; Li Q.; Yang H.; Jiang X.; Lin H.; Chen Y.; Qu W.; Feng F.; Bian Y.; Zhou Y.; Sun H.; Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer\u2019s disease. Bioorg Med Chem 2018,26(8),1665-1674","journal-title":"Bioorg Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3109\/14756366.2014.1003212","volume":"30","author":"Mao F.","year":"2015","unstructured":"Mao F.; Li J.; Wei H.; Huang L.; Li X.; Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer\u2019s disease. J Enzyme Inhib Med Chem 2015,30(6),995-1001","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejmech.2017.08.025","volume":"143","author":"Xu Y.X.","year":"2018","unstructured":"Xu Y.X.; Wang H.; Li X.K.; Dong S.N.; Liu W.W.; Gong Q.; Wang T.D.; Tang Y.; Zhu J.; Li J.; Zhang H.Y.; Mao F.; Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2018,143,33-47","journal-title":"Eur J Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.2174\/1568026617666170707130652","volume":"17","author":"Das S.","year":"2017","unstructured":"Das S.; Basu S.; Multi-targeting strategies for Alzheimer\u2019s disease therapeutics: Pros and cons. Curr Top Med Chem 2017,17(27),3017-3061","journal-title":"Curr Top Med Chem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2174\/1389200219666180305152553","volume":"19","author":"Batool A.","year":"2018","unstructured":"Batool A.; Kamal M.A.; Rizvi S.M.D.; Rashid S.; Topical discoveries on multi-target approach to manage Alzheimer\u2019s disease. Curr Drug Metab 2018,19(8),704-713","journal-title":"Curr Drug Metab"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.2174\/0929867326666181203124102","volume":"26","author":"Wang N.","year":"2019","unstructured":"Wang N.; Qiu P.; Cui W.; Yan X.; Zhang B.; He S.; Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present). Curr Med Chem 2019,26(30),5684-5710","journal-title":"Curr Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.2174\/0929867325666180111101843","volume":"25","author":"de Freitas Silva M.","year":"2018","unstructured":"de Freitas Silva M.; Dias K.S.T.; Gontijo V.S.; Ortiz C.J.C.; Viegas C.; Jr Multi-target directed drugs as a modern approach for drug design towards Alzheimer\u2019s disease: An update. Curr Med Chem 2018,25(29),3491-3525","journal-title":"Curr Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2174\/138955708785740652","volume":"8","author":"Bolognesi M.L.","year":"2008","unstructured":"Bolognesi M.L.; Minarini A.; Rosini M.; Tumiatti V.; Melchiorre C.; From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): A step forward in the treatment of Alzheimer\u2019s disease. Mini Rev Med Chem 2008,8(10),960-967","journal-title":"Mini Rev Med Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ejmech.2016.10.060","volume":"128","author":"Sameem B.","year":"2017","unstructured":"Sameem B.; Saeedi M.; Mahdavi M.; Shafiee A.; A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer\u2019s disease. Eur J Med Chem 2017,128,332-345","journal-title":"Eur J Med Chem"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.2174\/1568026618666180112161024","volume":"17","author":"Umar T.","year":"2017","unstructured":"Umar T.; Hoda N.; Alzheimer\u2019s disease: A systemic review of substantial therapeutic targets and the leading multi-functional molecules. Curr Top Med Chem 2017,17(31),3370-3389","journal-title":"Curr Top Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.bmc.2017.12.042","volume":"26","author":"Zhang X.","year":"2018","unstructured":"Zhang X.; He X.; Chen Q.; Lu J.; Rapposelli S.; Pi R.; A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimer\u2019s disease. Bioorg Med Chem 2018,26(3),543-550","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nurt.2008.10.030","volume":"6","author":"Weinreb O.","year":"2009","unstructured":"Weinreb O.; Mandel S.; Bar-Am O.; Yogev-Falach M.; Avramovich-Tirosh Y.; Amit T.; Youdim M.B.; Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer\u2019s disease drugs. Neurotherapeutics 2009,6(1),163-174","journal-title":"Neurotherapeutics"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejmech.2018.09.031","volume":"158","author":"Li Q.","year":"2018","unstructured":"Li Q.; He S.; Chen Y.; Feng F.; Qu W.; Sun H.; Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer\u2019s disease. Eur J Med Chem 2018,158,463-477","journal-title":"Eur J Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","volume":"176","author":"Zhang P.","year":"2019","unstructured":"Zhang P.; Xu S.; Zhu Z.; Xu J.; Multi-target design strategies for the improved treatment of Alzheimer\u2019s disease. Eur J Med Chem 2019,176,228-247","journal-title":"Eur J Med Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejmech.2019.02.076","volume":"169","author":"Wang T.","year":"2019","unstructured":"Wang T.; Liu X.H.; Guan J.; Ge S.; Wu M-B.; Lin J.P.; Yang L.R.; Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer\u2019s disease. Eur J Med Chem 2019,169,200-223","journal-title":"Eur J Med Chem"},{"key":"ref=105","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900177","volume":"352","author":"Mathew B.","year":"2019","unstructured":"Mathew B.; Parambi D.G.T.; Mathew G.E.; Uddin M.S.; Inasu S.T.; Kim H.; Marathakam A.; Unnikrishnan M.K.; Carradori S.; Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer\u2019s and Parkinson\u2019s diseases. Arch Pharm (Weinheim) 2019,352(11)","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2174\/15680266113139990120","volume":"13","author":"Y\u00e1\u00f1ez M.","year":"2013","unstructured":"Y\u00e1\u00f1ez M.; Vi\u00f1a D.; Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. Curr Top Med Chem 2013,13(14),1692-1706","journal-title":"Curr Top Med Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-2012-120013","volume":"30","author":"Zheng H.","year":"2012","unstructured":"Zheng H.; Amit T.; Bar-Am O.; Fridkin M.; Youdim M.B.; Mandel S.A.; From anti-Parkinson\u2019s drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer\u2019s disease. J Alzheimers Dis 2012,30(1),1-16","journal-title":"J Alzheimers Dis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1039\/C9MD00441F","volume":"11","author":"Wang X-B.","year":"2020","unstructured":"Wang X-B.; Yin F-C.; Huang M.; Jiang N.; Lan J-S.; Kong L-Y.; Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease. RSC Med Chem 2020,11(2),225-233","journal-title":"RSC Med Chem"},{"key":"ref=109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126900","volume":"30","author":"Yun Y.","year":"2020","unstructured":"Yun Y.; Yang J.; Miao Y.; Wang X.; Sun J.; Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer\u2019s disease agents. Bioorg Med Chem Lett 2020,30(4)","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103477","volume":"94","author":"Tian C.","year":"2020","unstructured":"Tian C.; Qiang X.; Song Q.; Cao Z.; Ye C.; He Y.; Deng Y.; Zhang L.; Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer\u2019s disease: Design, synthesis and biological evaluation. Bioorg Chem 2020,94","journal-title":"Bioorg Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejmech.2019.05.039","volume":"177","author":"Kumar B.","year":"2019","unstructured":"Kumar B.; Kumar V.; Prashar V.; Saini S.; Dwivedi A.R.; Bajaj B.; Mehta D.; Parkash J.; Kumar V.; Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase. Eur J Med Chem 2019,177,221-234","journal-title":"Eur J Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bioorg.2019.03.043","volume":"87","author":"Zhang X.","year":"2019","unstructured":"Zhang X.; Song Q.; Cao Z.; Li Y.; Tian C.; Yang Z.; Zhang H.; Deng Y.; Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer\u2019s disease. Bioorg Chem 2019,87,395-408","journal-title":"Bioorg Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejmech.2019.07.021","volume":"180","author":"Sang Z.","year":"2019","unstructured":"Sang Z.; Wang K.; Zhang P.; Shi J.; Liu W.; Tan Z.; Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2019,180,238-252","journal-title":"Eur J Med Chem"},{"key":"ref=114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111737","volume":"183","author":"Bai P.","year":"2019","unstructured":"Bai P.; Wang K.; Zhang P.; Shi J.; Cheng X.; Zhang Q.; Zheng C.; Cheng Y.; Yang J.; Lu X.; Sang Z.; Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer\u2019s disease. Eur J Med Chem 2019,183","journal-title":"Eur J Med Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ejmech.2019.06.026","volume":"178","author":"Sang Z.","year":"2019","unstructured":"Sang Z.; Wang K.; Shi J.; Liu W.; Tan Z.; Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2019,178,726-739","journal-title":"Eur J Med Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/acschemneuro.8b00530","volume":"10","author":"Sang Z.","year":"2019","unstructured":"Sang Z.; Wang K.; Han X.; Cao M.; Tan Z.; Liu W.; Design, synthesis, and evaluation of novel ferulic acid derivatives as multi-target-directed ligands for the treatment of Alzheimer\u2019s disease. ACS Chem Neurosci 2019,10(2),1008-1024","journal-title":"ACS Chem Neurosci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bioorg.2018.01.020","volume":"77","author":"Kumar B.","year":"2018","unstructured":"Kumar B.; Sheetal; Mantha, A.K.; Kumar, V. Synthesis, biological evaluation and molecular modeling studies of phenyl-\/benzhydrylpiperazine derivatives as potential MAO inhibitors. Bioorg Chem 2018,77,252-262","journal-title":"Bioorg Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/cmdc.201700589","volume":"13","author":"Kumar B.","year":"2018","unstructured":"Kumar B.; Kumar M.; Dwivedi A.R.; Kumar V.; Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl-Containing 2,4,6-Trisubstituted Pyrimidine Derivatives as Potential Anti-Parkinson Agents. ChemMedChem 2018,13(7),705-712","journal-title":"ChemMedChem"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1021\/acschemneuro.8b00220","volume":"10","author":"Kumar B.","year":"2019","unstructured":"Kumar B.; Dwivedi A.R.; Sarkar B.; Gupta S.K.; Krishnamurthy S.; Mantha A.K.; Parkash J.; Kumar V.; 4, 6-Diphenylpyrimidine derivatives as dual inhibitors of monoamine oxidase and acetylcholinesterase for the treatment of Alzheimer\u2019s disease. ACS Chem Neurosci 2019,10(1),252-265","journal-title":"ACS Chem Neurosci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1002\/slct.202002425","volume":"5","author":"Kumar V.","year":"2020","unstructured":"Kumar V.; Kumar B.; Ranjan Dwivedi A.; Mehta D.; Kumar N.; Bajaj B.; Arora T.; Prashar V.; Parkash J.; Kumar V.; Design, Synthesis and Evaluation of O\u2010Pentyne Substituted Diphenylpyrimidines as Monoamine Oxidase and Acetylcholinesterase Inhibitors. ChemistrySelect 2020,5(27),8021-8032","journal-title":"ChemistrySelect"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ddr.21631","volume":"81","author":"Chakravarty H.","year":"2020","unstructured":"Chakravarty H.; Ju Y.; Chen W.H.; Tam K.Y.; Dual targeting of cholinesterase and amyloid beta with pyridinium\/isoquinolium derivatives. Drug Dev Res 2020,81(2),242-255","journal-title":"Drug Dev Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.2174\/138161206778792985","volume":"12","author":"Castro A.","year":"2006","unstructured":"Castro A.; Martinez A.; Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 2006,12(33),4377-4387","journal-title":"Curr Pharm Des"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejmech.2016.12.048","volume":"127","author":"Je\u0159\u00e1bek J.","year":"2017","unstructured":"Je\u0159\u00e1bek J.; Uliassi E.; Guidotti L.; Kor\u00e1be\u010dn\u00fd J.; Soukup O.; Sepsova V.; Hrabinova M.; Ku\u010da K.; Bartolini M.; Pe\u00f1a-Altamira L.E.; Petralla S.; Monti B.; Roberti M.; Bolognesi M.L.; Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer\u2019s disease. Eur J Med Chem 2017,127,250-262","journal-title":"Eur J Med Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1016\/j.bmc.2017.02.048","volume":"25","author":"Yan J.","year":"2017","unstructured":"Yan J.; Hu J.; Liu A.; He L.; Li X.; Wei H.; Design, synthesis, and evaluation of multitarget-directed ligands against Alzheimer\u2019s disease based on the fusion of donepezil and curcumin. Bioorg Med Chem 2017,25(12),2946-2955","journal-title":"Bioorg Med Chem"},{"key":"ref=125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115400","volume":"28","author":"Luo L.","year":"2020","unstructured":"Luo L.; Song Q.; Li Y.; Cao Z.; Qiang X.; Tan Z.; Deng Y.; Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer\u2019s disease. Bioorg Med Chem 2020,28(8)","journal-title":"Bioorg Med Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/molecules23020347","volume":"23","author":"Panek D.","year":"2018","unstructured":"Panek D.; Wi\u0119ckowska A.; Pasieka A.; Gody\u0144 J.; Jo\u0144czyk J.; Bajda M.; Knez D.; Gobec S.; Malawska B.; Design, synthesis, and biological evaluation of 2-(Benzylamino-2-Hydroxyalkyl) Isoindoline-1, 3-diones derivatives as potential disease-modifying multifunctional anti-alzheimer agents. Molecules 2018,23(2),347","journal-title":"Molecules"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1021\/acschemneuro.7b00461","volume":"9","author":"Panek D.","year":"2018","unstructured":"Panek D.; Wi\u0119ckowska A.; Jo\u0144czyk J.; Gody\u0144 J.; Bajda M.; Wichur T.; Pasieka A.; Knez D.; Pi\u0161lar A.; Korabecny J.; Soukup O.; Sepsova V.; Sabat\u00e9 R.; Kos J.; Gobec S.; Malawska B.; Design, synthesis, and biological evaluation of 1-benzylamino-2-hydroxyalkyl derivatives as new potential disease-modifying multifunctional anti-Alzheimer\u2019s agents. ACS Chem Neurosci 2018,9(5),1074-1094","journal-title":"ACS Chem Neurosci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ejmech.2019.02.021","volume":"168","author":"Chalupova K.","year":"2019","unstructured":"Chalupova K.; Korabecny J.; Bartolini M.; Monti B.; Lamba D.; Caliandro R.; Pesaresi A.; Brazzolotto X.; Gastellier A-J.; Nachon F.; Pejchal J.; Jarosova M.; Hepnarova V.; Jun D.; Hrabinova M.; Dolezal R.; Zdarova Karasova J.; Mzik M.; Kristofikova Z.; Misik J.; Muckova L.; Jost P.; Soukup O.; Benkova M.; Setnicka V.; Habartova L.; Chvojkova M.; Kleteckova L.; Vales K.; Mezeiova E.; Uliassi E.; Valis M.; Nepovimova E.; Bolognesi M.L.; Kuca K.; Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer\u2019s disease. Eur J Med Chem 2019,168,491-514","journal-title":"Eur J Med Chem"},{"key":"ref=129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112180","volume":"192","author":"Sang Z.","year":"2020","unstructured":"Sang Z.; Wang K.; Shi J.; Liu W.; Cheng X.; Zhu G.; Wang Y.; Zhao Y.; Qiao Z.; Wu A.; Tan Z.; The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2020,192","journal-title":"Eur J Med Chem"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.bmc.2019.01.040","volume":"27","author":"Liu H.","year":"2019","unstructured":"Liu H.; Qiang X.; Song Q.; Li W.; He Y.; Ye C.; Tan Z.; Deng Y.; Discovery of 4\u00a2-OH-flurbiprofen Mannich base derivatives as potential Alzheimer\u2019s disease treatment with multiple inhibitory activities. Bioorg Med Chem 2019,27(6),991-1001","journal-title":"Bioorg Med Chem"},{"key":"ref=131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103006","volume":"89","author":"Riazimontazer E.","year":"2019","unstructured":"Riazimontazer E.; Sadeghpour H.; Nadri H.; Sakhteman A.; T\u00fcyl\u00fc K\u00fc\u00e7\u00fckk\u0131l\u0131n\u00e7 T.; Miri R.; Edraki N.; Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives. Bioorg Chem 2019,89","journal-title":"Bioorg Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejmech.2018.02.023","volume":"148","author":"Hiremathad A.","year":"2018","unstructured":"Hiremathad A.; Keri R.S.; Esteves A.R.; Cardoso S.M.; Chaves S.; Santos M.A.; Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer\u2019s disease. Eur J Med Chem 2018,148,255-267","journal-title":"Eur J Med Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/jnp.13.1.5","volume":"13","author":"Lanct\u00f4t K.L.","year":"2001","unstructured":"Lanct\u00f4t K.L.; Herrmann N.; Mazzotta P.; Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001,13(1),5-21","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/07853890008998828","volume":"32","author":"Buhot M-C.","year":"2000","unstructured":"Buhot M-C.; Martin S.; Segu L.; Role of serotonin in memory impairment. Ann Med 2000,32(3),210-221","journal-title":"Ann Med"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1021\/ol026418e","volume":"4","author":"Kogen H.","year":"2002","unstructured":"Kogen H.; Toda N.; Tago K.; Marumoto S.; Takami K.; Ori M.; Yamada N.; Koyama K.; Naruto S.; Abe K.; Yamazaki R.; Hara T.; Aoyagi A.; Abe Y.; Kaneko T.; Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer\u2019s disease. Org Lett 2002,4(20),3359-3362","journal-title":"Org Lett"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejmech.2016.08.016","volume":"124","author":"Wi\u0119ckowska A.","year":"2016","unstructured":"Wi\u0119ckowska A.; Ko\u0142aczkowski M.; Bucki A.; Gody\u0144 J.; Marcinkowska M.; Wi\u0119ckowski K.; Zar\u0119ba P.; Siwek A.; Kazek G.; G\u0142uch-Lutwin M.; Mierzejewski P.; Bienkowski P.; Sienkiewicz-Jarosz H.; Knez D.; Wichur T.; Gobec S.; Malawska B.; Novel multi-target-directed ligands for Alzheimer\u2019s disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. Eur J Med Chem 2016,124,63-81","journal-title":"Eur J Med Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1021\/acschemneuro.8b00024","volume":"9","author":"Wi\u0119ckowska A.","year":"2018","unstructured":"Wi\u0119ckowska A.; Wichur T.; Gody\u0144 J.; Bucki A.; Marcinkowska M.; Siwek A.; Wi\u0119ckowski K.; Zar\u0119ba P.; Knez D.; G\u0142uch-Lutwin M.; Kazek G.; Latacz G.; Mika K.; Ko\u0142aczkowski M.; Korabecny J.; Soukup O.; Benkova M.; Kie\u0107-Kononowicz K.; Gobec S.; Malawska B.; Novel multitarget-directed ligands aiming at symptoms and causes of Alzheimer\u2019s disease. ACS Chem Neurosci 2018,9(5),1195-1214","journal-title":"ACS Chem Neurosci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1021\/acschemneuro.7b00259","volume":"8","author":"Li X.","year":"2017","unstructured":"Li X.; Wang H.; Xu Y.; Liu W.; Gong Q.; Wang W.; Qiu X.; Zhu J.; Mao F.; Zhang H.; Li J.; Novel Vilazodone-Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer\u2019s Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. ACS Chem Neurosci 2017,8(12),2708-2721","journal-title":"ACS Chem Neurosci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2174\/1389450121666200310115327","volume":"21","author":"Kumar D.","year":"2020","unstructured":"Kumar D.; Sharma S.; Kalra S.; Singh G.; Monga V.; Kumar B.; Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies. Curr Drug Targets 2020,21(9),864-891","journal-title":"Curr Drug Targets"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"6937","DOI":"10.1021\/acs.jmedchem.8b00848","volume":"61","author":"Bautista-Aguilera O.M.","year":"2018","unstructured":"Bautista-Aguilera O.M.; Budni J.; Mina F.; Medeiros E.B.; Deuther-Conrad W.; Entrena J.M.; Moraleda I.; Iriepa I.; L\u00f3pez-Mu\u00f1oz F.; Marco-Contelles J.; Contilisant, a tetratarget small molecule for Alzheimer\u2019s disease therapy combining cholinesterase, monoamine oxidase inhibition, and H3R antagonism with S1R agonism profile. J Med Chem 2018,61(15),6937-6943","journal-title":"J Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"12765","DOI":"10.1002\/anie.201706072","volume":"56","author":"Bautista-Aguilera \u00d3.M.","year":"2017","unstructured":"Bautista-Aguilera \u00d3.M.; Hagenow S.; Palomino-Antolin A.; Farr\u00e9-Alins V.; Ismaili L.; Joffrin P.L.; Jimeno M.L.; Soukup O.; Jano\u010dkov\u00e1 J.; Kalinowsky L.; Proschak E.; Iriepa I.; Moraleda I.; Schwed J.S.; Romero Mart\u00ednez A.; L\u00f3pez-Mu\u00f1oz F.; Chioua M.; Egea J.; Ramsay R.R.; Marco-Contelles J.; Stark H.; Multitarget\u2010directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases. Angew Chem Int Ed Engl 2017,56(41),12765-12769","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-59805-7","volume":"10","author":"Lalut J.","year":"2020","unstructured":"Lalut J.; Payan H.; Davis A.; Lecoutey C.; Legay R.; Sopkova-de Oliveira Santos J.; Claeysen S.; Dallemagne P.; Rochais C.; Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT 4 receptors activities for the treatment of Alzheimer\u2019s disease. Sci Rep 2020,10(1),1-11","journal-title":"Sci Rep"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1039\/c2md20063e","volume":"3","author":"Lecoutey C.","year":"2012","unstructured":"Lecoutey C.; Rochais C.; Genest D.; Butt-Gueulle S.; Ballandonne C.; Corvaisier S.; Dulin F.; Lepailleur A.; Sopkova-de Oliveira Santos J.; Dallemagne P.; Synthesis of dual AChE\/5-HT 4 receptor multi-target directed ligands. MedChemComm 2012,3(5),627-634","journal-title":"MedChemComm"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","volume":"111","author":"Lecoutey C.","year":"2014","unstructured":"Lecoutey C.; Hedou D.; Freret T.; Giannoni P.; Gaven F.; Since M.; Bouet V.; Ballandonne C.; Corvaisier S.; Malzert Fr\u00e9on A.; Mignani S.; Cresteil T.; Boulouard M.; Claeysen S.; Rochais C.; Dallemagne P.; Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer\u2019s disease treatment. Proc Natl Acad Sci USA 2014,111(36),E3825-E3830","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fnagi.2019.00148","volume":"11","author":"Hatat B.","year":"2019","unstructured":"Hatat B.; Yahiaoui S.; Lecoutey C.; Davis A.; Freret T.; Boulouard M.; Claeysen S.; Rochais C.; Dallemagne P.; A novel in vivo antiamnesic agent, specially designed to express both acetylcholinesterase (AChE) inhibitory, serotonergic subtype 4 receptor (5-HT4R) agonist and serotonergic subtype 6 receptor (5-HT6R) inverse agonist activities, with a potential interest against Alzheimer\u2019s disease. Front Aging Neurosci 2019,11,148","journal-title":"Front Aging Neurosci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1006\/bbrc.1997.6357","volume":"232","author":"Reyes A.E.","year":"1997","unstructured":"Reyes A.E.; Perez D.R.; Alvarez A.; Garrido J.; Gentry M.K.; Doctor B.P.; Inestrosa N.C.; A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem Biophys Res Commun 1997,232(3),652-655","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"Inestrosa N.C.","year":"1996","unstructured":"Inestrosa N.C.; Alvarez A.; P\u00e9rez C.A.; Moreno R.D.; Vicente M.; Linker C.; Casanueva O.I.; Soto C.; Garrido J.; Acetylcholinesterase accelerates assembly of amyloid-\u03b2-peptides into Alzheimer\u2019s fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996,16(4),881-891","journal-title":"Neuron"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bmc.2018.01.030","volume":"26","author":"Cao Z.","year":"2018","unstructured":"Cao Z.; Yang J.; Xu R.; Song Q.; Zhang X.; Liu H.; Qiang X.; Li Y.; Tan Z.; Deng Y.; Design, synthesis and evaluation of 4\u00a2-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer\u2019s disease treatment. Bioorg Med Chem 2018,26(5),1102-1115","journal-title":"Bioorg Med Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/aps.2011.14","volume":"32","author":"Nie Q.","year":"2011","unstructured":"Nie Q.; Du X.G.; Geng M.Y.; Small molecule inhibitors of amyloid \u03b2 peptide aggregation as a potential therapeutic strategy for Alzheimer\u2019s disease. Acta Pharmacol Sin 2011,32(5),545-551","journal-title":"Acta Pharmacol Sin"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1046\/j.1432-1033.2002.03271.x","volume":"269","author":"Crescenzi O.","year":"2002","unstructured":"Crescenzi O.; Tomaselli S.; Guerrini R.; Salvadori S.; D\u2019Ursi A.M.; Temussi P.A.; Picone D.; Solution structure of the Alzheimer amyloid \u03b2-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 2002,269(22),5642-5648","journal-title":"Eur J Biochem"},{"key":"ref=151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115374","volume":"28","author":"Yang Z.","year":"2020","unstructured":"Yang Z.; Song Q.; Cao Z.; Yu G.; Liu Z.; Tan Z.; Deng Y.; Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer\u2019s disease. Bioorg Med Chem 2020,28(7)","journal-title":"Bioorg Med Chem"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ddr.10100","volume":"56","author":"Planel E.","year":"2002","unstructured":"Planel E.; Sun X.; Takashima A.; Role of GSK\u20103\u03b2 in Alzheimer\u2019s disease pathology. Drug Dev Res 2002,56(3),491-510","journal-title":"Drug Dev Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/med.10011","volume":"22","author":"Martinez A.","year":"2002","unstructured":"Martinez A.; Castro A.; Dorronsoro I.; Alonso M.; Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002,22(4),373-384","journal-title":"Med Res Rev"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","volume":"9","author":"Jiang X-Y.","year":"2018","unstructured":"Jiang X-Y.; Chen T-K.; Zhou J-T.; He S-Y.; Yang H-Y.; Chen Y.; Qu W.; Feng F.; Sun H-P.; Dual GSK-3\u03b2\/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer\u2019s disease drug discovery. ACS Med Chem Lett 2018,9(3),171-176","journal-title":"ACS Med Chem Lett"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejmech.2018.12.063","volume":"168","author":"Oukoloff K.","year":"2019","unstructured":"Oukoloff K.; Coquelle N.; Bartolini M.; Naldi M.; Le Gu\u00e9vel R.; Bach S.; Josselin B.; Ruchaud S.; Catto M.; Pisani L.; Denora N.; Iacobazzi R.M.; Silman I.; Sussman J.L.; Buron F.; Colletier J.P.; Jean L.; Routier S.; Renard P.Y.; Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. Eur J Med Chem 2019,168,58-77","journal-title":"Eur J Med Chem"},{"key":"ref=156","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/143269","volume":"2011","author":"Xu K.","year":"2011","unstructured":"Xu K.; Dai X.-L.; Huang H.-C.; Jiang Z.-F.;  Targeting HDACs: A promising therapy for Alzheimer's disease Oxid Med Cell Longev 2011,2011","journal-title":"Targeting HDACs: A promising therapy for Alzheimer's disease Oxid Med Cell Longev"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-017-0089-1","volume":"6","author":"Yang S.S.","year":"2017","unstructured":"Yang S.S.; Zhang R.; Wang G.; Zhang Y.F.; The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer\u2019s disease. Transl Neurodegener 2017,6(1),19","journal-title":"Transl Neurodegener"},{"key":"ref=158","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103721","volume":"98","author":"Xu A.","year":"2020","unstructured":"Xu A.; He F.; Zhang X.; Li X.; Ran Y.; Wei C.; James Chou C.; Zhang R.; Wu J.; Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer\u2019s disease: Design, synthesis, and biological evaluation. Bioorg Chem 2020,98","journal-title":"Bioorg Chem"},{"key":"ref=159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112193","volume":"192","author":"Tseng H-J.","year":"2020","unstructured":"Tseng H-J.; Lin M-H.; Shiao Y-J.; Yang Y-C.; Chu J-C.; Chen C-Y.; Chen Y-Y.; Lin T.E.; Su C-J.; Pan S-L.; Chen L.C.; Wang C.Y.; Hsu K.C.; Huang W.J.; Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer\u2019s disease. Eur J Med Chem 2020,192","journal-title":"Eur J Med Chem"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2202-12-125","volume":"12","author":"Zhu F.","year":"2011","unstructured":"Zhu F.; Wu F.; Ma Y.; Liu G.; Li Z.; Sun Y.; Pei Z.; Decrease in the production of \u03b2-amyloid by berberine inhibition of the expression of \u03b2-secretase in HEK293 cells. BMC Neurosci 2011,12(1),125","journal-title":"BMC Neurosci"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0169-409X(02)00157-6","volume":"54","author":"Vassar R.","year":"2002","unstructured":"Vassar R.; \u03b2-secretase (BACE) as a drug target for Alzheimer\u2019s disease. Adv Drug Deliv Rev 2002,54(12),1589-1602","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"Vassar R.","year":"2009","unstructured":"Vassar R.; Kovacs D.M.; Yan R.; Wong P.C.; The \u03b2-secretase enzyme BACE in health and Alzheimer\u2019s disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci 2009,29(41),12787-12794","journal-title":"J Neurosci"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1021\/acschemneuro.9b00430","volume":"10","author":"Sharma P.","year":"2019","unstructured":"Sharma P.; Tripathi A.; Tripathi P.N.; Singh S.S.; Singh S.P.; Shrivastava S.K.; Novel Molecular Hybrids of N-Benzylpiperidine and 1,3,4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer\u2019s Disease. ACS Chem Neurosci 2019,10(10),4361-4384","journal-title":"ACS Chem Neurosci"},{"key":"ref=164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111707","volume":"183","author":"Tripathi A.","year":"2019","unstructured":"Tripathi A.; Choubey P.K.; Sharma P.; Seth A.; Tripathi P.N.; Tripathi M.K.; Prajapati S.K.; Krishnamurthy S.; Shrivastava S.K.; Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer\u2019s disease. Eur J Med Chem 2019,183","journal-title":"Eur J Med Chem"},{"key":"ref=165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103025","volume":"89","author":"Mishra P.","year":"2019","unstructured":"Mishra P.; Sharma P.; Tripathi P.N.; Gupta S.K.; Srivastava P.; Seth A.; Tripathi A.; Krishnamurthy S.; Shrivastava S.K.; Design and development of 1,3,4-oxadiazole derivatives as potential inhibitors of acetylcholinesterase to ameliorate scopolamine-induced cognitive dysfunctions. Bioorg Chem 2019,89","journal-title":"Bioorg Chem"},{"key":"ref=166","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103506","volume":"95","author":"Tripathi A.","year":"2020","unstructured":"Tripathi A.; Choubey P.K.; Sharma P.; Seth A.; Saraf P.; Shrivastava S.K.; Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer\u2019s disease. Bioorg Chem 2020,95","journal-title":"Bioorg Chem"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/jhet.2594","volume":"54","author":"Mahdavi M.","year":"2017","unstructured":"Mahdavi M.; Saeedi M.; Gholamnia L.; Jeddi S.A.B.; Sabourian R.; Shafiee A.; Foroumadi A.; Akbarzadeh T.; Synthesis of novel tacrine analogs as acetylcholinesterase inhibitors. J Heterocycl Chem 2017,54(1),384-390","journal-title":"J Heterocycl Chem"},{"key":"ref=168","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201800488","volume":"16","author":"Mahdavi M.","year":"2019","unstructured":"Mahdavi M.; Hariri R.; Mirfazli S.S.; Lotfian H.; Rastergari A.; Firuzi O.; Edraki N.; Larijani B.; Akbarzadeh T.; Saeedi M.; Synthesis and Biological Activity of Some Benzochromenoquinolinones: Tacrine Analogs as Potent Anti-Alzheimer\u2019s Agents. Chem Biodivers 2019,16(4)","journal-title":"Chem Biodivers"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bioorg.2018.06.031","volume":"80","author":"Gabr M.T.","year":"2018","unstructured":"Gabr M.T.; Abdel-Raziq M.S.; Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors. Bioorg Chem 2018,80,245-252","journal-title":"Bioorg Chem"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"Cummings J.","year":"2019","unstructured":"Cummings J.; Lee G.; Ritter A.; Sabbagh M.; Zhong K.; Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019,5,272-293","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4172\/2155-9899.1000259","volume":"5","author":"Hebron M.L.","year":"2014","unstructured":"Hebron M.L.; Lonskaya I.; Olopade P.; Selby S.T.; Pagan F.; Moussa C.E.; Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in \u03b1-synucleinopathy. J Clin Cell Immunol 2014,5,259","journal-title":"J Clin Cell Immunol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"Hebron M.L.","year":"2013","unstructured":"Hebron M.L.; Lonskaya I.; Moussa C.E-H.; Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models. Hum Mol Genet 2013,22(16),3315-3328","journal-title":"Hum Mol Genet"},{"key":"ref=173","author":"Moussa C.","year":"2016","unstructured":"Moussa C.; Hebron M.; Li X.; Xu H.; Valadez E.; Yasar T-Y.; Rogers S.; Falconer D.; Mills R.; Pagan F.;  2016 International Congress 2016","journal-title":"2016 International Congress"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"Pagan F.","year":"2016","unstructured":"Pagan F.; Hebron M.; Valadez E.H.; Torres-Yaghi Y.; Huang X.; Mills R.R.; Wilmarth B.M.; Howard H.; Dunn C.; Carlson A.; Lawler A.; Rogers S.L.; Falconer R.A.; Ahn J.; Li Z.; Moussa C.; Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies. J Parkinsons Dis 2016,6(3),503-517","journal-title":"J Parkinsons Dis"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11064-014-1367-2","volume":"39","author":"Wang L.","year":"2014","unstructured":"Wang L.; Wang R.; Jin M.; Huang Y.; Liu A.; Qin J.; Chen M.; Wen S.; Pi R.; Shen W.; Carvedilol attenuates 6-hydroxydopamine-induced cell death in PC12 cells: Involvement of Akt and Nrf2\/ARE pathways. Neurochem Res 2014,39(9),1733-1740","journal-title":"Neurochem Res"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"2321.e1","DOI":"10.1016\/j.neurobiolaging.2010.05.004","volume":"32","author":"Wang J.","year":"2011","unstructured":"Wang J.; Ono K.; Dickstein D.L.; Arrieta-Cruz I.; Zhao W.; Qian X.; Lamparello A.; Subnani R.; Ferruzzi M.; Pavlides C.; Ho L.; Hof P.R.; Teplow D.B.; Pasinetti G.M.; Carvedilol as a potential novel agent for the treatment of Alzheimer\u2019s disease. Neurobiol Aging 2011,32(12),2321.e1-2321.e12","journal-title":"Neurobiol Aging"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","volume":"5","author":"Grundman M.","year":"2019","unstructured":"Grundman M.; Morgan R.; Lickliter J.D.; Schneider L.S.; DeKosky S.; Izzo N.J.; Guttendorf R.; Higgin M.; Pribyl J.; Mozzoni K.; Safferstein H.; Catalano S.M.; A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2019,5,20-26","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/npp.2013.70","volume":"38","author":"Lahmy V.","year":"2013","unstructured":"Lahmy V.; Meunier J.; Malmstr\u00f6m S.; Naert G.; Givalois L.; Kim S.H.; Villard V.; Vamvakides A.; Maurice T.; Blockade of Tau hyperphosphorylation and A\u03b2 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and \u03c3 receptor agonist, in a nontransgenic mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology 2013,38(9),1706-1723","journal-title":"Neuropsychopharmacology"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fncel.2014.00463","volume":"8","author":"Lahmy V.","year":"2015","unstructured":"Lahmy V.; Long R.; Morin D.; Villard V.; Maurice T.; Mitochondrial protection by the mixed muscarinic\/\u03c31 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A\u03b225-35 peptide-injected mice, a nontransgenic Alzheimer\u2019s disease model. Front Cell Neurosci 2015,8,463","journal-title":"Front Cell Neurosci"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0269881110379286","volume":"25","author":"Villard V.","year":"2011","unstructured":"Villard V.; Espallergues J.; Keller E.; Vamvakides A.; Maurice T.; Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma 1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol 2011,25(8),1101-1117","journal-title":"J Psychopharmacol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JAD-2012-111346","volume":"30","author":"Prasanthi J.R.","year":"2012","unstructured":"Prasanthi J.R.; Schrag M.; Dasari B.; Marwarha G.; Dickson A.; Kirsch W.M.; Ghribi O.; Deferiprone reduces amyloid-\u03b2 and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis 2012,30(1),167-182","journal-title":"J Alzheimers Dis"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1111\/j.1471-4159.2008.05332.x","volume":"105","author":"Molina-Holgado F.","year":"2008","unstructured":"Molina-Holgado F.; Gaeta A.; Francis P.T.; Williams R.J.; Hider R.C.; Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J Neurochem 2008,105(6),2466-2476","journal-title":"J Neurochem"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/156720506779025288","volume":"3","author":"Youdim M.B.","year":"2006","unstructured":"Youdim M.B.; The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 2006,3(5),541-550","journal-title":"Curr Alzheimer Res"},{"key":"ref=184","author":"Xiao S.","year":"2018","unstructured":"Xiao S.; Zhang Z.; Geng M.; Phase 3 Clinical Trial of a \tNovel and Multi-targeted Oligosaccharide in Patients with Mildmoderate AD in China GV-971 Study Group 2018"},{"key":"ref=185","first-page":"149","volume":"5","author":"Burstein A.H.","year":"2018","unstructured":"Burstein A.H.; Sabbagh M.; Andrews R.; Valcarce C.; Dunn I.; Altstiel L.; Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J Prev Alzheimers Dis 2018,5(2),149-154","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jalz.2018.06.716","volume":"14","year":"2018","unstructured":"Satlin, A.; Vanover, K.; Glass, S.; Saillard, J.; Mates, S.;\nWeingart, M.; Davis, R.E. ITI-007 (Lumateperone) for the\ntreatment of agitation in patients with dementia, including\nalzheimer\u2019s disease. Alzheimers Dement 2018,14(7),678-P 679","journal-title":"Alzheimers Dement"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210512005508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193293\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210512005508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T13:44:54Z","timestamp":1665495894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193293\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":186,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666210512005508","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}